METHOD FOR THE TREATMENT OF PROGRESSIVE CHRONIC INTERSTITIAL LUNG DISEASE

The present invention relates to an anti-transglutaminase type 2 antibody that blocks transamidase activity of the enzyme for use in the treatment of progressive chronic interstitial lung disease, such as Idiopathic pulmonary fibrosis (IPF).

Saved in:
Bibliographic Details
Main Authors SIME, Patricia J, THATCHER, Thomas Henry, JAMES, Ian Trollope, JOHNSON, Timothy Scott
Format Patent
LanguageEnglish
French
German
Published 25.09.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to an anti-transglutaminase type 2 antibody that blocks transamidase activity of the enzyme for use in the treatment of progressive chronic interstitial lung disease, such as Idiopathic pulmonary fibrosis (IPF).
Bibliography:Application Number: EP20220826056